MA51664A - Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide - Google Patents
Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amideInfo
- Publication number
- MA51664A MA51664A MA051664A MA51664A MA51664A MA 51664 A MA51664 A MA 51664A MA 051664 A MA051664 A MA 051664A MA 51664 A MA51664 A MA 51664A MA 51664 A MA51664 A MA 51664A
- Authority
- MA
- Morocco
- Prior art keywords
- cyclopropylmethyl
- isoxazole
- pyrimidin
- difluoro
- cyclopropyl
- Prior art date
Links
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 title 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 title 1
- IIDSHAJKXPUYSL-FPOVZHCZSA-N N-[(3S,4S)-1-(cyclopropylmethyl)-3-[(1-pyrimidin-2-ylcyclopropyl)carbamoyl]piperidin-4-yl]-5-(2,4-difluorophenyl)-1,2-oxazole-3-carboxamide Chemical compound N1=C(N=CC=C1)C1(CC1)NC(=O)[C@H]1CN(CC[C@@H]1NC(=O)C1=NOC(=C1)C1=C(C=C(C=C1)F)F)CC1CC1 IIDSHAJKXPUYSL-FPOVZHCZSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018051938 | 2018-01-26 | ||
| PCT/EP2019/051819 WO2019145460A1 (fr) | 2018-01-26 | 2019-01-25 | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-{[5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino}-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51664A true MA51664A (fr) | 2021-05-05 |
| MA51664B1 MA51664B1 (fr) | 2024-05-31 |
Family
ID=65139016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51664A MA51664B1 (fr) | 2018-01-26 | 2019-01-25 | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11339148B2 (fr) |
| EP (1) | EP3743422B1 (fr) |
| JP (1) | JP7076010B2 (fr) |
| KR (1) | KR102502046B1 (fr) |
| CN (1) | CN111683945B (fr) |
| AU (1) | AU2019212888B8 (fr) |
| BR (1) | BR112020015024A2 (fr) |
| CA (1) | CA3088478A1 (fr) |
| CL (1) | CL2020001928A1 (fr) |
| EA (1) | EA202091746A1 (fr) |
| IL (1) | IL276227B1 (fr) |
| MA (1) | MA51664B1 (fr) |
| MX (1) | MX2020007881A (fr) |
| PH (1) | PH12020551121A1 (fr) |
| SG (1) | SG11202006943TA (fr) |
| TW (1) | TWI822724B (fr) |
| UA (1) | UA125327C2 (fr) |
| WO (1) | WO2019145460A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3490986B1 (fr) | 2016-07-28 | 2021-11-24 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 pipéridine |
| AU2020372647A1 (en) | 2019-10-31 | 2022-06-16 | Idorsia Pharmaceuticals Ltd | Combination of a CXCR7 antagonist with an S1P1 receptor modulator |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050024A2 (fr) | 2002-11-27 | 2004-06-17 | Incyte Corporation | Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| WO2005032490A2 (fr) | 2003-10-08 | 2005-04-14 | Bristol-Myers Squibb Company | Diamines cycliques et derives comme inhibiteurs du facteur xa |
| BRPI0607756A2 (pt) | 2005-02-18 | 2010-05-18 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos |
| WO2009011850A2 (fr) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Nouveaux composés thérapeutiques |
| JP6094578B2 (ja) | 2011-06-09 | 2017-03-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン |
| WO2013084241A1 (fr) | 2011-12-09 | 2013-06-13 | Cadila Healthcare Limited | Composés inhibiteurs de rénine |
| AR091516A1 (es) | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| PT2925745T (pt) * | 2012-11-29 | 2018-08-08 | Chemocentryx Inc | Antagonistas de cxcr7 |
| CN105263924B (zh) | 2013-05-30 | 2018-10-19 | 爱杜西亚制药有限公司 | Cxcr7受体调节剂 |
| AU2014315457B2 (en) | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| ES2788848T3 (es) | 2013-09-06 | 2020-10-23 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| WO2015044900A1 (fr) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Composés immunomodulateurs thérapeutiques |
| KR20170047397A (ko) * | 2014-09-10 | 2017-05-04 | 에피자임, 인코포레이티드 | 치환된 피페리딘 화합물 |
| AU2015315173A1 (en) * | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted pyrrolidine compounds |
| WO2016087370A1 (fr) | 2014-12-01 | 2016-06-09 | Actelion Pharmaceuticals Ltd | Modulateurs du récepteur cxcr7 |
| EP3490986B1 (fr) * | 2016-07-28 | 2021-11-24 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 pipéridine |
-
2019
- 2019-01-25 MX MX2020007881A patent/MX2020007881A/es unknown
- 2019-01-25 CN CN201980010015.7A patent/CN111683945B/zh active Active
- 2019-01-25 UA UAA202005451A patent/UA125327C2/uk unknown
- 2019-01-25 JP JP2020560586A patent/JP7076010B2/ja active Active
- 2019-01-25 EP EP19701240.4A patent/EP3743422B1/fr active Active
- 2019-01-25 KR KR1020207024352A patent/KR102502046B1/ko active IP Right Grant
- 2019-01-25 WO PCT/EP2019/051819 patent/WO2019145460A1/fr unknown
- 2019-01-25 CA CA3088478A patent/CA3088478A1/fr active Pending
- 2019-01-25 TW TW108102825A patent/TWI822724B/zh active
- 2019-01-25 IL IL276227A patent/IL276227B1/en unknown
- 2019-01-25 EA EA202091746A patent/EA202091746A1/ru unknown
- 2019-01-25 BR BR112020015024-0A patent/BR112020015024A2/pt unknown
- 2019-01-25 AU AU2019212888A patent/AU2019212888B8/en active Active
- 2019-01-25 MA MA51664A patent/MA51664B1/fr unknown
- 2019-01-25 US US16/964,885 patent/US11339148B2/en active Active
- 2019-01-25 SG SG11202006943TA patent/SG11202006943TA/en unknown
-
2020
- 2020-07-23 CL CL2020001928A patent/CL2020001928A1/es unknown
- 2020-07-24 PH PH12020551121A patent/PH12020551121A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019212888A8 (en) | 2024-01-04 |
| PH12020551121A1 (en) | 2021-05-31 |
| BR112020015024A2 (pt) | 2021-01-19 |
| WO2019145460A1 (fr) | 2019-08-01 |
| EP3743422B1 (fr) | 2024-03-13 |
| TW201932460A (zh) | 2019-08-16 |
| CL2020001928A1 (es) | 2020-12-18 |
| IL276227B1 (en) | 2024-06-01 |
| CA3088478A1 (fr) | 2019-08-01 |
| EP3743422A1 (fr) | 2020-12-02 |
| JP2021511382A (ja) | 2021-05-06 |
| JP7076010B2 (ja) | 2022-05-26 |
| UA125327C2 (uk) | 2022-02-16 |
| CN111683945B (zh) | 2023-11-10 |
| CN111683945A (zh) | 2020-09-18 |
| SG11202006943TA (en) | 2020-08-28 |
| KR102502046B1 (ko) | 2023-02-20 |
| MX2020007881A (es) | 2022-06-02 |
| EA202091746A1 (ru) | 2020-11-26 |
| KR20200116115A (ko) | 2020-10-08 |
| AU2019212888A1 (en) | 2020-09-10 |
| IL276227A (en) | 2020-09-30 |
| EP3743422C0 (fr) | 2024-03-13 |
| AU2019212888B2 (en) | 2023-12-21 |
| TWI822724B (zh) | 2023-11-21 |
| US11339148B2 (en) | 2022-05-24 |
| MA51664B1 (fr) | 2024-05-31 |
| AU2019212888B8 (en) | 2024-01-04 |
| US20210115033A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170251A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ | |
| EA201991515A1 (ru) | N-[4-фтор-5-[[(2s,4s)-2-метил-4-[(5-метил-1,2,4-оксадиазол-3-ил)метокси]-1-пиперидил]метил]тиазол-2-ил]ацетамид в качестве ингибитора oga | |
| MA51664A (fr) | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide | |
| MD3601283T2 (ro) | Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată | |
| HRP20221389T1 (hr) | Inhibitori bromodomena | |
| MA28519B1 (fr) | Inhibiteurs de l'integrase du vih | |
| DK2091948T3 (da) | Nye inhibitorer af glutaminylcyclase | |
| MA37379A1 (fr) | Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| MA29120B1 (fr) | Sel de potassium d'un inhibiteur de l'integrase du vih | |
| MA32534B1 (fr) | Dérivés de cyclohexylamide et leur utilisation en tant qu'antagonistes des récepteurs de crf-1 | |
| NZ596579A (en) | Bace inhibitors | |
| EA200401194A1 (ru) | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение | |
| EA200800540A1 (ru) | Карбоксамидные производные в качестве антагонистов мускариновых рецепторов | |
| EA202192029A1 (ru) | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
| NZ594641A (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
| EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| BRPI0613664A8 (pt) | antagonista de 3-lactamil fenilalanina,cisteína e serina vasopressina | |
| JP2007523166A5 (fr) | ||
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| RU2017102513A (ru) | Соль гетероциклического соединения, замещенного галогеном | |
| MA54713A (fr) | Forme posologique parentérale stable d'acétate de cétrorélix | |
| PE20080271A1 (es) | Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1) | |
| EA202090925A1 (ru) | Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1 | |
| EA201992337A1 (ru) | Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов |